Ampio Pharmaceuticals, Inc.
(NYSE: AMPE)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") on behalf of stockholders. A class action complaint has been filed against Ampio. The complaint alleges that defendants made materially false and/or misleading statements, and failed to disclose material adverse facts about the Company's business operations and prospects. Specifically, defendants: (i) inflated the Company's true ability to successfully file a Biologics License Application for Ampio; (ii) inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) that, as a result, defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.